C4 Therapeutics, Inc.
C4 Therapeutics, Inc. (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company developing small-molecule medicines using targeted protein degradation, a process that harnesses the body’s mechanisms for destroying proteins. Its proprietary TORPEDO platform supports the design and optimization of degraders,… From the company’s description.
Over the twelve months to Sep 30, 2026, C4 Therapeutics, Inc. reported revenue of $32.28M, up 7.2% from a year earlier, and a net loss of $91.09M. Its operating margin was −315.9%, and operations used $79.63M in cash. In fiscal 2025, it reported revenue of $35.95M, up 1.0% from fiscal 2024, and a net loss of $104.99M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What C4 Therapeutics, Inc. does
In the company’s own words
C4 Therapeutics, Inc. (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company developing small-molecule medicines using targeted protein degradation, a process that harnesses the body’s mechanisms for destroying proteins. Its proprietary TORPEDO platform supports the design and optimization of degraders, including MonoDAC and BiDAC molecules, for oncology and discovery programs in inflammation, neuroinflammation, and neurodegenerative diseases. Its clinical-stage candidates include cemsidomide, an IKZF1/3 degrader being studied for multiple myeloma, and CFT8919, an EGFR L858R degrader for non-small-cell lung cancer; Betta Pharma leads CFT8919 development in Greater China. The company also conducts discovery collaborations with Roche and Merck KGaA, while Pfizer supplies elranatamab for a cemsidomide combination trial. C4 Therapeutics reported a net loss of $105.0 million for 2025, though it does not report product-sales revenue as its business is focused on research and development. Its website is www.c4therapeutics.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- WATERTOWN, MA
- Fiscal year end
- December
- CIK
- 1662579
- SIC
- 2836
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns C4 Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · C4 Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do C4 Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of C4 Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in C4 Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”